Contemporary Diagnosis of Very Low-risk Prostate Cancer in a Multihospital Health Care System

Richard Bennett 4th; Eric V Li; Austin Y Ho; Jonathan Aguiar; Ashorne K Mahenthiran; Chalairat Suk-Ouichai; Sai K Kumar; Clayton Neill; Edward M Schaeffer; Anugayathri Jawahar; Hiten D Patel; Ashley E Ross

doi:10.1016/j.euo.2024.04.015

Contemporary Diagnosis of Very Low-risk Prostate Cancer in a Multihospital Health Care System

Eur Urol Oncol. 2024 May 10:S2588-9311(24)00109-3. doi: 10.1016/j.euo.2024.04.015. Online ahead of print.

Affiliations

¹ Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: richbenn@iu.edu.
² Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³ Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
⁴ Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

PMID: 38734544
DOI: 10.1016/j.euo.2024.04.015

Abstract

The National Comprehensive Cancer Network (NCCN) very low risk (VLR) category for prostate cancer (PCa) represents clinically insignificant disease, and detection of VLR PCa contributes to overdiagnosis. Greater use of magnetic resonance imaging (MRI) and biomarkers before patient selection for prostate biopsy (PBx) reduces unnecessary biopsies and may reduce the diagnosis of clinically insignificant PCa. We tested a hypothesis that the proportion of VLR diagnoses has decreased with greater use of MRI-informed PBx using data from our 11-hospital system. From 2018 to 2023, 351/3197 (11%) men diagnosed with PCa met the NCCN VLR criteria. The proportion of VLR diagnoses did not change from 2018 to 2023 (p = 0.8) despite an increase in the use of MRI-informed PBx (from 49% to 82%; p < 0.001). Of patients who underwent combined systematic and targeted PBx and were diagnosed with VLR disease, cancer was found in systematic PBx regions in 79% of cases and in targeted PBx regions in 31% of cases. When performing both systematic and targeted PBx, prebiopsy MRI-based risk calculators could limit VLR diagnosis by 41% using a risk threshold of >5% for Gleason grade group ≥3 PCa to recommend biopsy; the reduction would be 77% if performing targeted PBx only. These findings suggest that VLR disease continues to account for a significant minority of PCa diagnoses and could be limited by targeted PBx and risk stratification calculators. PATIENT SUMMARY: We looked at recent trends for the diagnosis of very low-risk (VLR) prostate cancer. We found that VLR cancer still seems to be frequently diagnosed despite the use of MRI (magnetic resonance imaging) scans before biopsy. The use of risk calculators to identify men who could avoid biopsy and/or biopsy only for lesions that are visible on MRI could reduce the overdiagnosis of VLR prostate cancer.

Keywords: Magnetic resonance imaging risk calculator; Prostate cancer; Prostate cancer staging; Targeted biopsy.